Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts
Key facts
- Who runs it
- Rush University Medical Center
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 55 people, planned
- Started
- 2 Sept 2025
- Expected to end
- Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- 9-valent human papillomavirus vaccine
- Sterile Saline
- Record updated
- 15 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age 18 years or older
- Immunocompetent (no history of organ transplantation, active malignancy requiring immunosuppressive therapy, or HIV (human immunodeficiency virus) positive status)
- At least one wart that has been refractory to treatment
- At least two treatment modalities failed, including but not limited to:; cryotherapy, electrodesiccation, keratolytic agents, bleomycin, salicylic acid, excision
Who cannot take part
- Vulnerable populations, including immunocompromised status (active cancer, active tuberculosis (TB) - latent or previous history of these would not exclude patients)
- Previous severe reaction to HPV vaccination or known allergy to any vaccine component
- Younger than 18 years of age
- Unable to provide informed consent
- Pregnant
- Prisoner
Where in United States
- Rush University Medical CenterChicago, United States
About the trial
What the trial wants to find out
This study will evaluate whether Gardasil-9, a vaccine normally used to prevent human papillomavirus (HPV) infection, may be effective for treating recurring warts that have not responded to standard treatments. In this study, Gardasil-9 will be injected directly into a wart rather than into a muscle, which is an investigational use of the vaccine. Participants will be randomly assigned to receive injections of either Gardasil-9 or sterile saline (placebo) directly into a wart. Neither the participant nor the clinician administering the injection will know which treatment is being given. The study will evaluate participants during treatment and follow-up visits to assess their warts and quality of life.
The 2 groups in the trial
- Intralesional Gardasil-9Treatment being tested
Participants randomized to this arm will receive 9-valent human papillomavirus (HPV) vaccine (Gardasil-9) administered by intralesional injection into the selected wart or warts. Up to three warts may be treated during a treatment visit. Participants will return approximately every 4-6 weeks for evaluation and may receive additional treatment if the treated wart or warts have not resolved.
Treatment: 9-valent human papillomavirus vaccine
- Intralesional Sterile Saline PlaceboPlacebo, for comparison
Participants randomized to this arm will receive sterile saline administered by intralesional injection as the placebo comparator. Participants will return approximately every 4-6 weeks for evaluation and may receive additional blinded treatment if the treated wart or warts have not resolved. After completion of the blinded study period and disclosure of treatment assignment, participants who received sterile saline will have the option to receive intralesional Gardasil-9 during the open-label extension.
Treatment: Sterile Saline
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Placebo-Controlled Trial of Intralesional Gardasil-9 Vaccine for the Treatment of Recalcitrant Verrucae
- Record updated
- 15 September 2026